MCAULAY CAMERON (Chief Financial Officer) received a stock award from TRANSPHORM, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 9/1/2023ACC: 0001209191-23-047936
Officer· Chief Financial Officer
Since Feb 2020
+176K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
176K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+105.60K
Price / share
—
Trade value
—
% of position
124.8%
8/30/2023
84.63K→190.23K
Total
Net shares
+105.60K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/30/2023 | A · Award | +105.60K | — | — | 124.8% | 84.63K | 190.23K |
| Total | +105.60K | $0.00 | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
70.40K shares
Shares
+70.40K
Strike price
2.80
Held after
70.40K
Exercisable
—
8/30/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock70.40K shares | 8/30/2023 | A · Award | +70.40K | 2.80 | — | 70.40K |